The AR/ARD1/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer
Translational Research · 2026-12 · 298 · 57-71
DOI: 10.1016/j.trsl.2026.09.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2026-12. Verfasst von Chongwu He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang 330029, Jiangxi, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptors, Androgen, B7-H1 Antigen, Carcinogenesis. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, Education Department of Jiangxi Province, Health Commission of Jiangxi Province.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) poses a significant clinical challenge due to its aggressive nature and lack of targeted therapies. A subset expressing the Androgen Receptor (AR) offers a therapeutic opportunity, yet the mechanisms remain incompletely understood. Breast cells were cultured under hormone-deprived or androgen-stimulated conditions with or without AR inhibitors. Short hairpin RNA knockdown or overexpression of AR, ARD1, and DLGAP5 was performed. Functional assays included CCK-8, colony formation, migration and invasion, and apoptosis by flow cytometry. Protein interactions and transcriptional regulation were examined using co-immunoprecipitation and chromatin immunoprecipitation. In vivo, xenograft models of TNBC were established in BALB/c nude mice. Clinical relevance was validated using paired TNBC and adjacent normal tissues. AR and ARD1 were co-upregulated in AR+ TNBC cells and tissues, correlating with poor prognosis. ARD1 promoted TNBC malignant phenotypes in vitro and in vivo. Mechanistically, androgens induced ARD1 protein stabilization via AR. ARD1 physically interacted with AR, enhanced AR acetylation, and potentiated AR transcriptional activity. DLGAP5 was identified as a transcriptional target co-regulated by AR and ARD1. DLGAP5 upregulation promoted tumor growth and drove expression of the immune checkpoint ligand PD-L1 via signal transducer and activator of transcription 3, suppressing cytotoxic T-cell marker expression. In vivo, DLGAP5 overexpression accelerated tumor growth and increased PD-L1; treatment with an AR PROTAC reversed these effects. ARD1 acts as a critical AR coactivator, driving DLGAP5 expression, which subsequently promotes tumor progression and immune evasion through PD-L1 upregulation. Targeting the AR/ARD1/DLGAP5 axis represents a promising therapeutic strategy for this breast cancer subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang 330029, Jiangxi, China.
- Department of Pathology, Jiangxi Dian Hua Xing Medical Laboratory Co., Ltd, Nanchang 330029, Jiangxi, China.
- Department of Nursing, Nanchang Medical College, Nanchang 330052, Jiangxi, China.
- Department of Thyroid and Breast Surgery, Xing'an League People's Hospital, Xing'an League, Ulanhot 137400, China.
- Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi, China.
- Department of Breast Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang 330029, Jiangxi, China. Electronic address: wanxh1996@163.com.
Förderung
- Natural Science Foundation of Jiangxi Province
- Education Department of Jiangxi Province
- Health Commission of Jiangxi Province
Zitieren
APA
He, C., Zhou, B., Chen, J., Tian, R., Zeng, X., Wan, X., Yu, T., & Zou, J. (2026). The AR/ARD1/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer. Translational Research, 298, 57-71. https://doi.org/10.1016/j.trsl.2026.09.011
Vancouver
He C, Zhou B, Chen J, Tian R, Zeng X, Wan X, et al. The AR/ARD1/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer. Translational Research. 2026;298:57-71. doi:10.1016/j.trsl.2026.09.011
BibTeX
@article{He2026,
author = {He, Chongwu and Zhou, Bin and Chen, Jing and Tian, Ruibo and Zeng, Xiaoqiang and Wan, Xianghua and Yu, Tenghua and Zou, Jun},
title = {The AR/ARD1/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer},
journal = {Translational Research},
year = {2026},
volume = {298},
pages = {57--71},
doi = {10.1016/j.trsl.2026.09.011}
}
EUVIMED